Additionally, LIMK inhibitors are considered potential therapeutic agents for various indications, including elevated intraocular pressure (IOP), cancer, and HIV-1 infection, with LX-7101 advancing to Phase I clinical trials for glaucoma treatment [19]. This evidence concerns the gene LIMK1 and cancer.